Evolution in the Surgical Management of Gastric Cancer Peritoneal Metastases.

Despite therapeutic treatments and the growing utilization of multimodal therapies, gastric cancer (GC) remains a highly aggressive malignancy with high mortality worldwide. Much of the complexity in treating GC is due to the high incidence of peritoneal metastasis (PM), with mean overall survival typically ranging from 4 to 10 months. With current systemic therapy, targeted therapies, and immunotherapies continuing to remain ineffective for GC/PM, there has been a significant growing interest in intraperitoneal (IP) therapies for the treatment of GC/PM.

Prospects of the Surgical Management of Colorectal Peritoneal Metastasis.

Background: Colorectal cancer (CRC) is a common malignancy with the propensity to metastasize. Common sites of metastasis include the liver, lung, and peritoneum with peritoneal metastases (PM) having the worst prognosis. Unfortunately, systemic chemotherapy is often less effective in the treatment of peritoneal metastases.